We are a clinical stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic vision-threatening diseases of the retina and optic nerve.
Our pipeline leverages our proprietary ocular delivery technologies, which are designed to maintain potent and effective drug levels in ocular tissue for up to 12 months and potentially longer, to improve patient compliance, reduce healthcare burdens and ultimately improve clinical outcomes.
We are developing our lead product candidate, GB-102, an inhibitor of multiple neovascular pathways, for the intravitreal, or IVT, treatment of retinal diseases, including wet age-related macular degeneration, or wet AMD, with a six-month dosing regimen.
In September 2019, we initiated a dose-ranging, double-blind Phase 2b clinical trial, ALTISSIMO, designed to evaluate the safety and efficacy of GB-102 in patients with wet AMD compared to bi-monthly IVT injections of aflibercept, marketed as Eylea.
We are also using our proprietary technologies to develop GB-401, a novel treatment for primary open angle glaucoma, or POAG, with a dosing regimen of up to six months, and GB-103, which utilizes the same active ingredient as GB-102, sunitinib, and is designed to deliver therapeutic drug levels of sunitinib to the retinal tissue for 12 months from a single IVT injection.
We believe our proprietary ocular delivery technologies will allow us to develop therapeutics that achieve extended durations of effectiveness that will ultimately improve the care and quality of life for patients with chronic diseases and disorders of the eye.